Latest / The Well-Built Life / Oncology's Evolution: Treatments
Transcript
- 0:00Speaker 1: Hey everyone, welcome back to The Well-Built Life. I am
- 0:03Speaker 1: Rachel Caldwell, alongside Thomas Bennett, and we are so glad
- 0:07Speaker 1: you are tuning in. We are here to cut through
- 0:10Speaker 1: the noise, skip the intense jargon and extreme rules, and
- 0:14Speaker 1: share simple practical habits that help you feel stronger, healthier,
- 0:18Speaker 1: and more balanced every single day. Grab a drink, get comfortable,
- 0:22Speaker 1: and let's dive in. So, let's start with what is
- 0:25Speaker 1: happening behind the scenes here. It's one thing to see
- 0:28Speaker 1: cancer statistics and diagnoses on the rise. But when you
- 0:31Speaker 1: dive into the research, it's a bit more complex than
- 0:34Speaker 1: meets the eye. Brett Bogelstein's 2015 paper in Science came
- 0:39Speaker 1: as a shock to many in the field, really rewriting
- 0:42Speaker 1: our understanding of cancer.
- 0:43Speaker 2: Exactly. Because on the surface, it looks straightforward. But when
- 0:47Speaker 2: you dig into the mechanics, the incentives tell a very
- 0:51Speaker 2: different story. For years, cancer was seen primarily as a
- 0:55Speaker 2: genetic problem. But Vogelstein's research shifted that perspective. They found
- 1:00Speaker 2: that about two-thirds of mutations in cancers are random, which
- 1:03Speaker 2: is a significant shift from our previous understanding.
- 1:06Speaker 1: Right, and that's the crucial nuance here. It's not just
- 1:10Speaker 1: about the genes, but also about our environment and metabolism.
- 1:14Speaker 1: This paper really set the stage for a re-evaluation of prevention, detection,
- 1:19Speaker 1: and treatment strategies. It's like flipping a coin. where the
- 1:23Speaker 1: outcome is largely determined by chance rather than a direct
- 1:27Speaker 1: genetic predisposition.
- 1:28Speaker 2: That's wild when you look at the raw numbers. In
- 1:31Speaker 2: the paper, they cited that about 66% of mutations were random,
- 1:35Speaker 2: 30% were environmental triggers, and only 5% were hereditary. That
- 1:41Speaker 2: means a lot of cancer cases aren't just about the genes.
- 1:45Speaker 2: They are influenced by lifestyle factors and environmental exposures. It's
- 1:49Speaker 2: changing how we look at cancer as both a genetic
- 1:53Speaker 2: and environmental disease.
- 1:54Speaker 1: So, as we move forward, we have seen an interesting
- 1:57Speaker 1: shift in therapeutic modalities. We are now incorporating more targeted
- 2:01Speaker 1: metabolic approaches alongside the resurgence of epidemiologic research. Immunotherapy, for example,
- 2:08Speaker 1: has extended survival and offered curative potential for certain cancers.
- 2:13Speaker 1: Take CAR T-cell therapy. which is really making a big
- 2:16Speaker 1: impact on treating blood cancers. It's fascinating how these treatments
- 2:21Speaker 1: are tailored to individual patients.
- 2:24Speaker 2: Exactly. And it's not just about the therapies. Therese, a
- 2:28Speaker 2: multifaceted approach integrating genetics, inflammation, and metabolism. For instance, obesity
- 2:34Speaker 2: is a major risk factor in certain cancers like endometrial cancer.
- 2:39Speaker 2: But it's not just the genes. The environment and diet
- 2:42Speaker 2: play significant roles. The interplay of these factors is key
- 2:46Speaker 2: to understanding and addressing the issue.
- 2:48Speaker 1: Right. And the rise of artificial intelligence in cancer diagnostics
- 2:52Speaker 1: is also adding another layer to this. AI can help
- 2:55Speaker 1: with early detection and personalized treatment plans. But there are
- 2:59Speaker 1: some challenges too, like high rates of false positives leading
- 3:02Speaker 1: to unnecessary interventions. The goal is to strike a balance here.
- 3:06Speaker 2: True. The use of AI can be a game changer,
- 3:09Speaker 2: but we need to be smart about how we implement it.
- 3:12Speaker 2: It's not just about detecting cancer, it's about doing it
- 3:15Speaker 2: accurately and responsibly, so we are not over-diagnosing and causing
- 3:19Speaker 2: undue stress and unnecessary treatments. This intersection of AI and
- 3:24Speaker 2: healthcare is still very much an area of active research.
- 3:28Speaker 1: And as we continue to explore this, the role of
- 3:31Speaker 1: AI developers and data scientists becomes increasingly important, but so
- 3:36Speaker 1: do the patients, oncologists, and pharmaceutical companies. The stakeholders are diverse,
- 3:42Speaker 1: and they all have a crucial part to play. The
- 3:45Speaker 1: challenge is to ensure that all these different perspectives are
- 3:49Speaker 1: integrated seamlessly.
- 3:50Speaker 2: Absolutely. The future of oncology is going to be shaped
- 3:54Speaker 2: by the interplay of all these factors. It's an exciting
- 3:57Speaker 2: yet complex landscape. As we look ahead, there are still
- 4:01Speaker 2: unsolved questions like how to identify and manage mutations in
- 4:05Speaker 2: patient care, and whether lifestyle modifications can significantly impact cancer risk.
- 4:10Speaker 2: The future is ripe with possibilities, but it also poses
- 4:15Speaker 2: significant challenges.
- 4:16Speaker 1: Well, it's clear that the field is moving in a
- 4:18Speaker 1: direction that is more personalized and data-driven. But it's important
- 4:23Speaker 1: to remember that there is still a lot of work
- 4:25Speaker 1: to do. The more we refine our understanding, the better
- 4:29Speaker 1: we can tailor treatments and preventions to individual needs. That's
- 4:34Speaker 1: the ultimate goal. let's delve into the impact of genetic predispositions. Thomas,
- 4:40Speaker 1: as we mentioned earlier, about 5% of cancers are due
- 4:44Speaker 1: to hereditary factors. What are the key genes we should
- 4:47Speaker 1: be aware of when considering genetic predispositions?
- 4:50Speaker 2: Absolutely, Rachel. The BRCA1 and BRCA2 genes are perhaps the
- 4:55Speaker 2: most well-known examples, primarily linked to breast and ovarian cancers. However,
- 5:01Speaker 2: there are other important genes as well, like Lynch syndrome,
- 5:05Speaker 2: which increases the risk of colorectal and ovarian cancers. So,
- 5:10Speaker 2: when screening for hereditary cancers, it's crucial to look beyond
- 5:14Speaker 2: BRCA1 and BRCA2.
- 5:16Speaker 1: Right, and these hereditary mutations we are talking about, they
- 5:20Speaker 1: can be categorized into shove or nudge. Can you explain
- 5:23Speaker 1: this to our listeners?
- 5:25Speaker 2: Certainly. A shove mutation occurs when a genetic alteration is
- 5:29Speaker 2: so severe that it's almost inevitable for cancer to develop.
- 5:34Speaker 2: A nudge, on the other hand, is a genetic variation
- 5:37Speaker 2: that can increase risk but doesn't guarantee cancer. For example,
- 5:41Speaker 2: if you carry a shove mutation, you have a significantly
- 5:45Speaker 2: higher risk. But if you have a nudge mutation, the
- 5:48Speaker 2: increased risk may be more subtle and harder to manage effectively.
- 5:52Speaker 1: That's a really insightful distinction. Now, let's talk about lifestyle influences. Obesity,
- 5:59Speaker 1: for instance, has a 30% risk factor in certain cancers.
- 6:03Speaker 1: What other lifestyle factors should we consider?
- 6:06Speaker 2: Along with obesity, diet, physical activity, smoking, and alcohol consumption
- 6:12Speaker 2: are also major contributors. Chronic inflammation, often linked to poor
- 6:16Speaker 2: lifestyle choices, can trigger genetic mutations that promote cancer development.
- 6:21Speaker 2: For instance, a diet high in processed foods and low
- 6:25Speaker 2: in antioxidants can increase oxidative stress, which damages DNA and
- 6:29Speaker 2: potentially leads to cancer.
- 6:31Speaker 1: Fascinating. That brings us to the role of AI in
- 6:34Speaker 1: identifying early stage cancers. How exactly is AI being used here?
- 6:39Speaker 2: AI is being used in several ways. Liquid biopsies, for example,
- 6:44Speaker 2: use machine learning algorithms to detect circulating tumor DNA in
- 6:48Speaker 2: the blood. This can help identify early stage cancers before
- 6:52Speaker 2: they become more aggressive. Additionally, AI can analyze large sets
- 6:56Speaker 2: of imaging data to detect subtle changes that might indicate
- 7:00Speaker 2: the presence of cancer at an early stage, reducing the
- 7:03Speaker 2: need for invasive biopsies.
- 7:04Speaker 1: That's an impressive use of technology. But as you mentioned,
- 7:08Speaker 1: to raise a challenge with false positives, how are researchers
- 7:12Speaker 1: addressing this issue?
- 7:13Speaker 2: It's a valid concern. Researchers are working on improving the
- 7:17Speaker 2: accuracy of these AI models by integrating more extensive datasets
- 7:22Speaker 2: and refining the algorithms to minimize false positive rates. The
- 7:26Speaker 2: goal is to develop a highly sensitive and specific diagnostic
- 7:30Speaker 2: tool that doesn't just detect anomalies, but also correctly interprets
- 7:34Speaker 2: their clinical significance.
- 7:36Speaker 1: Exactly. That brings us to the ethics of genetic sequencing.
- 7:40Speaker 1: How should patients be informed about their genetic risks? And
- 7:44Speaker 1: what are the consent issues?
- 7:45Speaker 2: Ethical considerations are crucial in this domain. Patients need to
- 7:49Speaker 2: be fully informed about the implications of genetic testing, including
- 7:53Speaker 2: potential psychological impacts to raise a risk of causing undue
- 7:57Speaker 2: stress or anxiety. so it's important for healthcare providers to
- 8:01Speaker 2: handle this information sensitively. Moreover, there are legal and regulatory issues,
- 8:07Speaker 2: particularly regarding how genetic information is stored and used by
- 8:11Speaker 2: insurance companies and employers.
- 8:13Speaker 1: And finally, as we look to the future, what are
- 8:16Speaker 1: the key areas of research that need to be explored further?
- 8:20Speaker 2: On the horizon, Teresa need to better understand how nudges
- 8:23Speaker 2: mutations can be effectively managed. Additionally, Research needs to focus
- 8:28Speaker 2: on how lifestyle modifications, such as diet and exercise, can
- 8:32Speaker 2: reduce cancer risk. The integration of AI and machine learning
- 8:36Speaker 2: into clinical practice will continue to evolve, offering new tools
- 8:40Speaker 2: for early detection and personalized treatment.
- 8:43Speaker 1: Thomas, you have really outlined a compelling argument. It's clear
- 8:47Speaker 1: that the landscape of oncology is moving rapidly, driven by
- 8:51Speaker 1: both genetic and lifestyle factors. And with the help of AI,
- 8:55Speaker 1: we are making significant strides in prevention and early detection.
- 8:59Speaker 1: But Therese, still much work to be done. Now, Thomas,
- 9:03Speaker 1: let's dive into some of the most exciting advancements in
- 9:06Speaker 1: cancer treatment today. Immunotherapy, targeted therapies, and surgical innovations are
- 9:12Speaker 1: transforming how we approach cancer care. And AI coding platforms
- 9:16Speaker 1: are playing a pivotal role in making all of this possible.
- 9:19Speaker 2: Absolutely, Rachel. With immunotherapy. the focus shifts towards harnessing the
- 9:24Speaker 2: body's immune system to fight cancer. For instance, CAR T-cell
- 9:28Speaker 2: therapy is showing impressive results in treating blood cancers like leukemia.
- 9:33Speaker 2: Imagine taking a patient's T-cells, genetically engineering them to target
- 9:37Speaker 2: cancer cells, and infusing them back into the body. That's
- 9:40Speaker 2: a pretty radical shift from traditional chemo and radiation.
- 9:45Speaker 1: That's exactly right. It's not just about the therapy itself.
- 9:48Speaker 1: It's also about the patient's journey. CAR T-cell therapy can
- 9:52Speaker 1: be life-changing, though the treatment comes with its own set
- 9:55Speaker 1: of risks and side effects, like cytokine release syndrome, where
- 9:59Speaker 1: the immune system overreacts. We are still working on how
- 10:03Speaker 1: to mitigate these risks in a personalized treatment plan.
- 10:06Speaker 2: Right, and that's where AI comes into play. Agi platforms
- 10:09Speaker 2: are analyzing patient data, predicting who might respond best to
- 10:13Speaker 2: CAR-T therapy, and even helping tailor the treatment to minimize
- 10:16Speaker 2: side effects. For example, AI models can predict which mutations
- 10:21Speaker 2: are more likely to cause a severe reaction, allowing doctors
- 10:25Speaker 2: to adjust the dosage or even provide preemptive support.
- 10:28Speaker 1: Exactly. AI is not just about diagnostics. It's also about
- 10:33Speaker 1: optimizing treatment. Moving on to targeted therapies, we have novel
- 10:38Speaker 1: biologics and small molecule drugs that are designed to target
- 10:42Speaker 1: specific genetic mutations. These aren't just random mutations.
- 10:47Speaker 2: Thomas.
- 10:48Speaker 1: But ones that are known to play a key role
- 10:50Speaker 1: in cancer development. For instance, her two mutations in breast
- 10:54Speaker 1: cancer can be specifically targeted with drugs like trastuzumab, significantly
- 11:00Speaker 1: improving outcomes.
- 11:01Speaker 2: And it's not just breast cancer. Targeted therapies are revolutionizing
- 11:06Speaker 2: treatment for many cancers, including lung, colon, and melanoma. The
- 11:10Speaker 2: key is to find the right target and the right
- 11:13Speaker 2: patient to maximize efficacy. Imagine being able to sequence a
- 11:17Speaker 2: patient's tumor and create a personalized treatment plan based on
- 11:21Speaker 2: the specific mutations present. That's the future, and AI is
- 11:26Speaker 2: at the heart of it.
- 11:26Speaker 1: Right? And surgical innovations are also moving forward. Minimally invasive
- 11:31Speaker 1: techniques are not only less traumatic for patients, but are
- 11:34Speaker 1: also leading to better outcomes. Robotics, in particular, allows for
- 11:39Speaker 1: incredibly precise procedures with smaller incisions, leading to faster recoveries
- 11:45Speaker 1: and less pain. It's a game changer for both the
- 11:48Speaker 1: patient and the surgeon.
- 11:50Speaker 2: Absolutely. And AI is once again taking center stage here.
- 11:54Speaker 2: By integrating machine learning, AI platforms can help surgeons plan better,
- 11:59Speaker 2: predict outcomes, and even assist in real-time during operations. For example,
- 12:04Speaker 2: with robotic surgery, AI can enhance the surgeon's capabilities by
- 12:09Speaker 2: providing real-time feedback. and suggesting the next optimal move, which
- 12:14Speaker 2: could be the difference between success and failure in a
- 12:17Speaker 2: delicate procedure.
- 12:18Speaker 1: That's a great point. AI is like the co-pilot in
- 12:21Speaker 1: these cases, making sure every decision is informed and every
- 12:25Speaker 1: step is precise. And as we continue to refine these technologies,
- 12:30Speaker 1: the integration of AI will only become more seamless, ultimately
- 12:34Speaker 1: leading to better patient outcomes and more personalized care.
- 12:38Speaker 2: Exactly. The future of cancer treatment is looking more optimistic
- 12:42Speaker 2: than ever, thanks to these advancements. Whether it's through immunotherapy,
- 12:46Speaker 2: targeted therapies, or surgical innovations, the role of AI is undeniable.
- 12:52Speaker 2: It's not just a tool, it's a partner in this
- 12:54Speaker 2: journey to find better ways to fight cancer.
- 12:57Speaker 1: So, let's take a closer look at the contradictions and
- 13:00Speaker 1: ethical considerations surrounding genetic sequencing and how they impact personalized care,
- 13:06Speaker 1: as we have seen. The hereditary mutations like BRCA1 and
- 13:10Speaker 1: BRCA2 can predict some risk, but they are just one
- 13:14Speaker 1: piece of the puzzle.
- 13:15Speaker 2: Absolutely, Rachel. The balance between hereditary and random mutations is
- 13:19Speaker 2: a key contradiction in this field. While hereditary cancers might
- 13:23Speaker 2: be easier to detect and manage due to clear genetic markers,
- 13:27Speaker 2: the majority of cancers arise from random mutations, which are
- 13:30Speaker 2: harder to predict and prevent. For instance … The BRCA1
- 13:35Speaker 2: and BRCA2 genes only account for about 5% of all
- 13:39Speaker 2: breast cancers, leaving us with a lot of room for
- 13:42Speaker 2: other factors.
- 13:43Speaker 1: Right. And this brings us to the ethical considerations. With
- 13:47Speaker 1: the ability to sequence genomes and identify these genetic markers,
- 13:52Speaker 1: we are walking a fine line between providing valuable information
- 13:56Speaker 1: and causing undue anxiety. Take the case of the high-risk
- 14:00Speaker 1: individual who learns they carry a predisposing gene. the psychological
- 14:04Speaker 1: impact can be significant, especially if they are unaware of
- 14:08Speaker 1: the full spectrum of lifestyle factors that also play a role.
- 14:12Speaker 2: Exactly. That's the crux of the matter. It's not just
- 14:15Speaker 2: about the gene. It's about understanding the nuances. For example,
- 14:20Speaker 2: while BRCA1 and BRCA2 increase the risk, lifestyle factors like
- 14:25Speaker 2: obesity can significantly impact outcomes. About 30% of endometrial cancers,
- 14:30Speaker 2: for instance, are linked to obesity. highlighting the complex interplay
- 14:34Speaker 2: between genetics and environment.
- 14:36Speaker 1: That's wild when you look at the raw numbers. And
- 14:39Speaker 1: it's not just endometrial cancer. Many cancers show a similar pattern.
- 14:44Speaker 1: This complexity underscores the need for personalized care that considers
- 14:48Speaker 1: both genetic and lifestyle factors.
- 14:50Speaker 2: Indeed, and that's where AI comes in. AI coding platforms
- 14:55Speaker 2: like AGI can help in identifying early-stage cancers more accurately,
- 14:59Speaker 2: but we have to be mindful of the potential for overdiagnosis.
- 15:03Speaker 2: The challenge is to use AI without causing unnecessary harm,
- 15:07Speaker 2: especially since many of these early-stage detections might not require intervention.
- 15:11Speaker 1: That's a valid point, Thomas. The debate around genetic sequencing
- 15:16Speaker 1: extends beyond just the detection phase. For example, take the
- 15:20Speaker 1: consent process. How do we handle patient consent when we
- 15:23Speaker 1: are sequencing their genome, especially if it's a hereditary condition
- 15:28Speaker 1: that could affect their family? It's a delicate balance between
- 15:31Speaker 1: offering life-saving information and respecting individual autonomy.
- 15:36Speaker 2: Right. And that's the crucial nuance here. Patient consent is
- 15:41Speaker 2: a complex issue, especially when it comes to hereditary conditions.
- 15:46Speaker 2: We need frameworks that ensure patients are fully informed and
- 15:49Speaker 2: involved in decision-making processes, but we also need to be
- 15:53Speaker 2: realistic about the possibility of negative outcomes from this information.
- 15:57Speaker 1: Exactly. Which brings up an interesting contradiction. On one hand,
- 16:01Speaker 1: we have the potential to save lives through early detection
- 16:05Speaker 1: and personalized treatment. But on the other, we have the
- 16:08Speaker 1: risk of causing harm through over-diagnosis and undue stress. It's
- 16:13Speaker 1: a fine line we have to tread carefully. Indeed.
- 16:16Speaker 2: And as we look to the future, the integration of
- 16:19Speaker 2: AI and machine learning will only become more crucial. These
- 16:23Speaker 2: tools can help in refining early detection methods and personalized
- 16:27Speaker 2: treatment plans. but we must ensure that they are used
- 16:30Speaker 2: ethically and responsibly. Agreed.
- 16:33Speaker 1: The future of cancer care is exciting, but we must
- 16:35Speaker 1: approach it with a balanced perspective, considering both the potential
- 16:39Speaker 1: benefits and the ethical challenges. It's about finding that sweet
- 16:44Speaker 1: spot where science and ethics meet.
- 16:45Speaker 2: Absolutely, Rachel. Let's focus on driving that progress in a
- 16:49Speaker 2: way that benefits patients and respects their autonomy.
- 16:53Speaker 1: So, we have talked about the exciting advancements in cancer care,
- 16:56Speaker 1: and the role of AI in diagnostics. Now, let's dive
- 17:01Speaker 1: into some of the unsolved questions and future research directions.
- 17:05Speaker 1: For example, the phenomenon of tumor dormancy. This is where
- 17:09Speaker 1: we have a real mix of science and mystery.
- 17:12Speaker 2: Exactly, and it's a fascinating area. We still don't fully
- 17:15Speaker 2: understand what triggers tumor dormancy or what makes it regress.
- 17:19Speaker 2: What kind of research is being conducted to uncover these mechanisms?
- 17:23Speaker 1: Well, it's multifaceted. One approach is looking at the genetic
- 17:27Speaker 1: and metabolic profiles of tumors in dormancy. Researchers are exploring
- 17:32Speaker 1: how small changes in gene expression or metabolic pathways might
- 17:36Speaker 1: be responsible. For instance, it's hypothesized that tumors in dormancy
- 17:41Speaker 1: might be more sensitive to certain metabolic stressors.
- 17:44Speaker 2: That's wild when you look at the raw numbers. For example,
- 17:48Speaker 2: consider the work done in melanoma. Some researchers found that
- 17:52Speaker 2: reducing insulin-like growth factor signaling in dormant cells actually increased
- 17:57Speaker 2: their survival. It's like the tumor is in a state
- 18:00Speaker 2: of metabolic weight and C.
- 18:02Speaker 1: Right. It brings up an interesting contradiction. Why do these
- 18:06Speaker 1: tumors wake up sometimes, but not others? Some researchers are
- 18:10Speaker 1: trying to figure out the environmental cues that might be
- 18:13Speaker 1: resetting the tumor's state, like the balance between sleep and wake.
- 18:18Speaker 1: only much more complex in biology.
- 18:20Speaker 2: That really harkens back to the nudge versus shove hypothesis.
- 18:24Speaker 2: Some researchers think that external factors can push a tumor
- 18:28Speaker 2: from dormancy back into active growth. For example, changes in
- 18:32Speaker 2: the host's immune response or even dietary patterns. That's why
- 18:37Speaker 2: lifestyle modifications could play a big role. But we still
- 18:40Speaker 2: need more evidence.
- 18:41Speaker 1: Absolutely. And on the topic of AI, we are starting
- 18:44Speaker 1: to see these tools applied in interesting ways. For instance,
- 18:48Speaker 1: machine learning models are being used to predict which patients
- 18:52Speaker 1: might enter a dormant state based on their genetic and
- 18:54Speaker 1: metabolic profiles. This could help in early intervention and personalized
- 18:59Speaker 1: treatment strategies.
- 19:00Speaker 2: That's incredibly promising, but we mustn't forget the ethical considerations.
- 19:06Speaker 2: For example, how do we ensure that patient data is
- 19:10Speaker 2: used responsibly? And how do we balance the benefits of
- 19:13Speaker 2: AI diagnostics with the risk of overdiagnosis or misdiagnosis?
- 19:18Speaker 1: Exactly. Which brings up an interesting point. As we move forward,
- 19:22Speaker 1: it's crucial to have a strong dialogue between data scientists, oncologists,
- 19:27Speaker 1: and patients themselves. We need clear guidelines to ensure that
- 19:32Speaker 1: AI tools are used ethically and effectively.
- 19:35Speaker 2: Agreed, Rachel. And it's not just about the tools. It's
- 19:38Speaker 2: about the human elements of care. How do we integrate
- 19:42Speaker 2: these advancements into existing clinical practices? How do we make
- 19:46Speaker 2: sure that patients understand their treatment options and feel empowered
- 19:49Speaker 2: to make informed decisions?
- 19:51Speaker 1: That's the real challenge. We are seeing a lot of progress,
- 19:55Speaker 1: but it's a slow and intricate process. The future of
- 19:58Speaker 1: personalized cancer care will depend on how well we can
- 20:02Speaker 1: navigate these complexities together. That brings us to the end
- 20:05Speaker 1: of today's episode. Thank you so much for spending part
- 20:08Speaker 1: of your day with me. If you found this episode's
- 20:10Speaker 1: tips helpful and want to make sure you don't miss
- 20:12Speaker 1: the next conversation, please take a quick second to hit
- 20:15Speaker 1: that subscribe or follow button on whatever platform you are
- 20:18Speaker 1: listening on. It's a completely free way to support the
- 20:21Speaker 1: show and helps more people find us. This podcast is
- 20:24Speaker 1: independently produced, so if you are ever in a position
- 20:28Speaker 1: where you would like to help keep it running, we
- 20:30Speaker 1: do accept small donations. You can find a link right
- 20:33Speaker 1: in the episode description below to buy us a coffee
- 20:36Speaker 1: or contribute what you can. Every bit genuinely helps. Take
- 20:41Speaker 1: care of yourself, stay balanced, and we will talk again soon.